Eiger BioPharmaceuticals, Inc. (EIGRQ) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Eiger BioPharmaceuticals, Inc. (EIGRQ) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 54/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 16 mar 2026Eiger BioPharmaceuticals, Inc. (EIGRQ) Resumen de Asistencia Médica y Tuberías
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in therapies for hepatitis delta virus (HDV) and rare diseases like Hutchinson-Gilford progeria syndrome. Their lead product, Zokinvy, addresses progeria, while Lonafarnib targets HDV. The company is currently navigating Chapter 11 reorganization.
Tesis de Inversión
Eiger BioPharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity. The company's focus on rare diseases and HDV, a significant unmet medical need, offers potential for substantial growth if Lonafarnib gains regulatory approval and achieves commercial success. However, the recent Chapter 11 filing introduces significant uncertainty and risk. The company's gross margin of 95.1% indicates strong pricing power for its existing product, Zokinvy. Investors should closely monitor the bankruptcy proceedings, clinical trial outcomes for Lonafarnib and Peginterferon Lambda, and the company's ability to secure financing and restructure its operations. The company's beta of 2.78 suggests high volatility.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market Cap of $0.01B reflects the company's distressed valuation following the Chapter 11 filing.
- Gross Margin of 95.1% indicates strong pricing power for Zokinvy, the company's commercialized product.
- P/E Ratio of -0.17 indicates the company is currently unprofitable.
- Profit Margin of -475.3% highlights the significant losses the company is incurring.
- Chapter 11 filing on April 1, 2024, introduces substantial risk and uncertainty for investors.
Competidores y Pares
Fortalezas
- Approved product (Zokinvy) generating revenue.
- Promising pipeline of product candidates targeting unmet medical needs.
- Expertise in developing therapies for rare diseases.
- Strong gross margin.
Debilidades
- Chapter 11 bankruptcy filing.
- High operating losses and negative profit margin.
- Dependence on regulatory approval for pipeline products.
- Limited financial resources.
Catalizadores
- Upcoming: Potential regulatory approval of Lonafarnib for HDV.
- Ongoing: Progress in Chapter 11 bankruptcy proceedings.
- Ongoing: Clinical trial results for Peginterferon Lambda.
- Ongoing: Development of Avexitide for hyperinsulinism.
Riesgos
- Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.
- Potential: Failure to obtain regulatory approval for pipeline products.
- Potential: Competition from other companies developing therapies for similar diseases.
- Potential: Inability to secure financing to fund operations.
- Potential: Limited liquidity and price volatility on the OTC market.
Oportunidades de crecimiento
- Lonafarnib Approval for HDV: Lonafarnib represents a significant growth opportunity for Eiger. HDV affects millions globally, and an approved therapy could generate substantial revenue. The Phase 3 clinical trials have been completed, and regulatory approval is the next step. The timeline for approval depends on the FDA review process, but potential approval could occur within the next 12-18 months, pending the resolution of the Chapter 11 reorganization.
- Peginterferon Lambda Development: Peginterferon Lambda is in clinical development for HDV and has also been investigated for COVID-19. The potential market for HDV treatment is substantial, and success in this area could drive significant growth. Further clinical trial results and regulatory decisions will determine the timeline and market potential.
- Avexitide for Hyperinsulinism: Avexitide, currently in Phase II development for congenital hyperinsulinism and post-bariatric hypoglycemia, addresses a niche market with limited treatment options. Successful clinical trials and regulatory approval could provide a valuable revenue stream. The timeline for commercialization depends on the progress of clinical trials and regulatory review.
- Expansion of Zokinvy Market: Zokinvy, approved for Hutchinson-Gilford progeria syndrome, can be expanded to new geographies and patient populations. While progeria is a rare disease, increasing awareness and diagnosis can drive growth. The company can also explore new formulations or indications for Zokinvy to further expand its market potential.
- Strategic Partnerships and Acquisitions: Eiger can pursue strategic partnerships or acquisitions to expand its product pipeline and market reach. Collaborations with other biotechnology companies or research institutions can accelerate the development of new therapies and provide access to new technologies. The company's Chapter 11 reorganization may impact its ability to pursue such opportunities in the near term.
Oportunidades
- Regulatory approval of Lonafarnib for HDV.
- Expansion of Zokinvy market to new geographies and patient populations.
- Strategic partnerships and collaborations to expand pipeline.
- Development of new therapies for other rare diseases.
Amenazas
- Failure to obtain regulatory approval for pipeline products.
- Competition from other companies developing therapies for similar diseases.
- Uncertainty related to Chapter 11 bankruptcy proceedings.
- Inability to secure financing to fund operations.
Ventajas competitivas
- Patents and intellectual property protection for its therapies.
- Regulatory exclusivity for approved products, such as Zokinvy.
- Specialized expertise in developing therapies for rare diseases.
- Established relationships with key opinion leaders and patient advocacy groups.
Acerca de EIGRQ
Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for serious diseases with unmet medical needs. The company's lead product, Zokinvy, is approved for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Additionally, Eiger is developing Lonafarnib, an orally available farnesylation inhibitor, for the treatment of Hepatitis Delta Virus (HDV) infection, a disease with no approved therapies until recently. Peginterferon Lambda (lambda) is another product candidate in clinical development for HDV and has also been investigated for mild and moderate COVID-19. Avexitide is in Phase II development for congenital hyperinsulinism and post-bariatric hypoglycemia. Founded to address rare and orphan diseases, Eiger has evolved into a commercial-stage company with a focus on HDV and other serious conditions. Headquartered in Palo Alto, California, Eiger BioPharmaceuticals filed for Chapter 11 reorganization on April 1, 2024.
Qué hacen
- Develop and commercialize therapies for hepatitis delta virus (HDV).
- Offer Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome.
- Develop Lonafarnib, an orally available farnesylation inhibitor, for HDV infection.
- Develop Peginterferon Lambda (lambda) for HDV and COVID-19.
- Develop Avexitide for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
Modelo de Negocio
- Develop and obtain regulatory approval for pharmaceutical products.
- Manufacture and market approved products directly or through partnerships.
- Generate revenue through the sale of pharmaceutical products.
- Invest in research and development to discover and develop new therapies.
Contexto de la Industria
Eiger BioPharmaceuticals operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on niche markets such as rare diseases and HDV, where there are limited treatment options and significant unmet medical needs. The competitive landscape includes companies developing therapies for viral infections and rare genetic disorders. The biotechnology industry is driven by innovation and regulatory approvals, with market trends favoring targeted therapies and personalized medicine.
Clientes Clave
- Patients with Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.
- Patients with Hepatitis Delta Virus (HDV) infection.
- Patients with congenital hyperinsulinism and post-bariatric hypoglycemia.
- Healthcare providers who prescribe and administer Eiger's therapies.
Finanzas
Gráfico e información
Precio de la acción de Eiger BioPharmaceuticals, Inc. (EIGRQ): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para EIGRQ.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para EIGRQ.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para EIGRQ.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de EIGRQ en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: David Apelian
CEO
David Apelian serves as the CEO of Eiger BioPharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on clinical development and commercialization. Prior to joining Eiger, he held leadership positions at various pharmaceutical companies, overseeing the development and launch of several successful products. His expertise spans multiple therapeutic areas, including infectious diseases and rare genetic disorders. He is responsible for managing 25 employees.
Historial: Under David Apelian's leadership, Eiger BioPharmaceuticals has achieved key milestones, including the approval and commercialization of Zokinvy for Hutchinson-Gilford progeria syndrome. He has also overseen the advancement of Lonafarnib through Phase 3 clinical trials for HDV. The Chapter 11 filing occurred during his tenure, presenting a significant challenge for the company.
Información del mercado OTC de EIGRQ
The OTC Other tier represents the lowest tier of the OTC market, indicating that Eiger BioPharmaceuticals, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, are in financial distress, or have chosen not to comply with higher reporting standards. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for low trading volume and price volatility.
- Increased risk of fraud or manipulation.
- Uncertainty related to the company's Chapter 11 bankruptcy proceedings.
- Difficulty in obtaining reliable financial information.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Review the company's business plan and growth strategy.
- Evaluate the company's competitive position and market opportunities.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Commercial-stage biopharmaceutical company with an approved product (Zokinvy).
- Focus on developing therapies for serious diseases with unmet medical needs.
- Experienced management team with a background in the biopharmaceutical industry.
- Completion of Phase 3 clinical trials for Lonafarnib.
- Listing on the OTC market, indicating some level of public trading.
Preguntas Comunes Sobre EIGRQ
¿Cuáles son los factores clave para evaluar EIGRQ?
Eiger BioPharmaceuticals, Inc. (EIGRQ) actualmente tiene una puntuación IA de 54/100, indicando puntuación moderada. Fortaleza clave: Approved product (Zokinvy) generating revenue.. Riesgo principal a monitorear: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de EIGRQ?
EIGRQ actualmente puntúa 54/100 (Grado C) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de EIGRQ?
Los precios de EIGRQ se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre EIGRQ?
La cobertura de analistas para EIGRQ incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en EIGRQ?
Las categorías de riesgo para EIGRQ incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de EIGRQ?
La relación P/E para EIGRQ compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está EIGRQ sobrevalorada o infravalorada?
Determinar si Eiger BioPharmaceuticals, Inc. (EIGRQ) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de EIGRQ?
Eiger BioPharmaceuticals, Inc. (EIGRQ) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- The company's Chapter 11 bankruptcy proceedings introduce significant uncertainty.